Kairos Pharma (KAPA) EBIAT (2024 - 2025)
Historic EBIAT for Kairos Pharma (KAPA) over the last 2 years, with Q2 2025 value amounting to -$1.4 million.
- Kairos Pharma's EBIAT fell 46205.53% to -$1.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$4.7 million, marking a year-over-year change of. This contributed to the annual value of -$2.6 million for FY2024, which is 4365.34% down from last year.
- Latest data reveals that Kairos Pharma reported EBIAT of -$1.4 million as of Q2 2025, which was down 46205.53% from -$1.3 million recorded in Q1 2025.
- Kairos Pharma's 5-year EBIAT high stood at -$253000.0 for Q2 2024, and its period low was -$1.4 million during Q2 2025.